Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus for Hemorrhagic Brainstem Cavernous Malformations
NCT06091332Phase 2Recruiting
- Sponsor
- Huashan Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus in cavernous malformation (CCM), sponsored by Huashan Hospital. Started Jan 2024; status: recruiting.
02
Drugs
sirolimus
03
Conditions
cavernous malformation (CCM)
Beyond the preview
Go deeper on NCT06091332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06091332.